ClinicalTrialsFinder
RecruitingNot ApplicableNCT07122713

Definitive Radiation Therapy for Inoperable Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

Sponsor

Alexander Stessin

Enrollment

30 participants

Start Date

Dec 8, 2025

Study Type

INTERVENTIONAL

Conditions

Breast CancerBreast Adenocarcinoma

Summary

The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing definitive (curative-intent) radiation therapy as a primary treatment for people with breast cancer who cannot have surgery, to see if it can effectively control the cancer. **You may be eligible if...** - You have biopsy-confirmed invasive breast cancer (any stage from early to locally advanced, T1–T4) - You are not able to have surgery due to the cancer being too advanced to remove, or because surgery is considered too risky for your health - You do not have confirmed spread to distant organs (M0 or limited M1) **You may NOT be eligible if...** - You are a good candidate for standard breast cancer surgery - You have certain conditions that make radiation therapy unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor

Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions

RADIATIONWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes

Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions

Locations(1)

Stony Brook University Cancer Center

Stony Brook, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07122713

Related Trials

Genomic Services Research Program

NCT025959571 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location